-+ 0.00%
-+ 0.00%
-+ 0.00%

Lytix Biopharma Plans Phase III Trial Preparations for Ruxotemitide in Neoadjuvant Melanoma

PUBT·11/18/2026 00:47:12
Listen to the news
Lytix Biopharma Plans Phase III Trial Preparations for Ruxotemitide in Neoadjuvant Melanoma
  • Lytix Biopharma will use proceeds from its NOK 80 million capital raise to prepare ruxotemitide for Phase III in neoadjuvant melanoma.
  • Funding will also support the Phase II ALETTA melanoma study, advance LTX-401 toward Phase I and cover general corporate purposes.
  • The planned Phase III trial will require additional financing or a partner.
  • A subsequent offering could raise up to NOK 15 million at NOK 8 per share, subject to market conditions and other requirements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief via Cision (Ref. ID: 20261117:BIT:0628:0) on November 18, 2026, and is solely responsible for the information contained therein.